This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Arbutus (ABUS) Stock Might be a Great Pick
by Zacks Equity Research
Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Arbutus' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Arbutus Biopharma.
Moving Average Crossover Alert: Arbutus Biopharma
by Zacks Equity Research
Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 21.88% and -17.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 2.70% and 10.34%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in Arbutus Biopharma (ABUS) Stock
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down
by Zacks Equity Research
Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of -200.00% and -68.53%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of -31.43% and -20.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
by Zacks Equity Research
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of -51.61% and -40.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
by Ekta Bagri
We take a look at companies, which have been developing treatments for various diseases using RNAi technology.
Top Ranked Momentum Stocks to Buy for April 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 8th.
Top Ranked Momentum Stocks to Buy for November 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 23rd:
Options Traders Expect Huge Moves in Arbutus (ABUS) Stock
by Zacks Equity Research
Arbutus (ABUS) needs investors to pay close attention to the stock based on moves in the options market lately.
Arbutus Biopharma (ABUS) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
by Zacks Equity Research
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arbutus (ABUS) stock based on the movements in the options market lately.
Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation (ABUS)